Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PT Enseval Putera Megatrading Tbk EBITDA Margin % Related Terms
PT Enseval Putera Megatrading Tbk EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:EPMT vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, PT Enseval Putera Megatrading Tbk's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Enseval Putera Megatrading Tbk EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, PT Enseval Putera Megatrading Tbk's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PT Enseval Putera Megatrading Tbk's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Enseval Putera Megatrading Tbk (ISX:EPMT) has a EBITDA Margin % of 4.40% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PT Enseval Putera Megatrading Tbk and its competitors. This is near median its historical median of 4.38. Over the past decade, PT Enseval Putera Megatrading Tbk's EBITDA Margin % has ranged from 3.64 to 4.94. According to the industry distribution chart, PT Enseval Putera Megatrading Tbk ranks #68 out of 119 companies in the Medical Distribution industry, placing it in the top 57.1%.
Is PT Enseval Putera Megatrading Tbk's EBITDA Margin % too high?
PT Enseval Putera Megatrading Tbk's current EBITDA Margin % of 4.40% is near median its 10-year median of 4.38. Over the past 10 years, this metric has ranged from a low of 3.64 to a high of 4.94. The Medical Distribution industry median EBITDA Margin % is 4.11. PT Enseval Putera Megatrading Tbk's value of 4.40% is 7.1% above this industry median. Based on the distribution chart, PT Enseval Putera Megatrading Tbk ranks #68 out of 119 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, PT Enseval Putera Megatrading Tbk has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Enseval Putera Megatrading Tbk's EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, PT Enseval Putera Megatrading Tbk ranks #68 out of 119 companies for EBITDA Margin %. This places PT Enseval Putera Megatrading Tbk in the lower half of its industry. The industry median EBITDA Margin % is 4.11. PT Enseval Putera Megatrading Tbk's value of 4.40% is 7.1% above this benchmark. Historically, PT Enseval Putera Megatrading Tbk's own EBITDA Margin % has ranged from 3.64 to 4.94 over the past decade. While the company's 10-year median is 4.38 vs. the industry median of 4.11, PT Enseval Putera Megatrading Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.11, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Enseval Putera Megatrading Tbk's current EBITDA Margin % of 4.40% is 7.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PT Enseval Putera Megatrading Tbk and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Enseval Putera Megatrading Tbk's current EBITDA Margin % is 4.40%, which is near median its own 10-year median of 4.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Enseval Putera Megatrading Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Enseval Putera Megatrading Tbk (ISX:EPMT) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp2,689.14, compared to a current price of Rp2,360.00 — trading 12.2% below its estimated fair value. The current EBITDA Margin % is 4.40%, which is near median its 10-year median of 4.38 and 7.1% above the Medical Distribution industry median of 4.11. PT Enseval Putera Megatrading Tbk's overall GF Score™ is 89/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PT Enseval Putera Megatrading Tbk (ISX:EPMT), the current EBITDA Margin % is 4.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Enseval Putera Megatrading Tbk (ISX:EPMT) Overvalued in 2026?
Based on GuruFocus' analysis, PT Enseval Putera Megatrading Tbk stock appears to be undervalued.
The current stock price of Rp2,360.00 is trading 12.2% below its estimated GF Value™ of Rp2,689.14.
GuruFocus considers PT Enseval Putera Megatrading Tbk to be Modestly Undervalued.
Key valuation signals for ISX:EPMT:
EBITDA Margin %: 4.40% (near median its 10-year median of 4.38)
GF Value™: Rp2,689.14 vs. price of Rp2,360.00 (12.2% below fair value)
Industry Position: 7.1% above the Medical Distribution median (#68 of 119)
No single metric tells the full story. See the ISX:EPMT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Enseval Putera Megatrading Tbk is a general distributor dealing in pharmaceutical products, consumer products, and medical devices. The company also acts as an agent and distributor of consumer goods, prescription medicines, non-prescription medicines, raw materials for the pharmaceutical, medical equipment, including marketing activities, veterinary medicines, cosmetics, and other industries. The company's business segments are Pharmaceuticals which generates maximum revenue; Consumer products, and Others.
89GF Score
Get the complete analysis for ISX:EPMT
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:EPMT has been successfully added to your 
